Selling Psychedelics

Abstract

Psychedelic therapies—ketamine, MDMA, psilocybin, LSD, DMT, and ibogaine—are moving from prohibition to regulated care, but commercialization hinges on FDA approval, DEA scheduling, and payor (insurance) coverage. This Article maps the U.S. regulatory labyrinth and analyzes how business models succeed or fail under these constraints. It explains bifurcated rescheduling (DEA reschedules the approved drug product, not the underlying Schedule I substance), and why coverage often follows FDA approval despite the high cost of clinical trials. Case studies track (1) ketamine’s split path: Janssen’s FDA-approved esketamine (Spravato) and off-label ketamine clinic chains; (2) MDMA’s “pseudo-nonprofit” pathway (MAPS, MAPS PBC, Lykos), including revenue-purchase financing (Vine Ventures) to fund Phase 3 trials; and (3) psilocybin’s IP divide: Usona’s nonprofit, open-science strategy (with Porta Sophia prior-art defenses) versus Compass Pathways’ for-profit, patent-driven route (COMP360, FDA Breakthrough Therapy). The Article distills practical takeaways on insurance strategy (on-label pathways, ancillary benefits, assisted-therapy billing), nonprofit/for-profit structuring, and patent freedom-to-operate that generalize to future psychedelic products. The framework offers regulators, payors, investors, and counsel a grounded playbook for scaling evidence-based access while avoiding IP bottlenecks and reputational traps.